Company Overview and News

 
Colorectal Cancer Pipeline 2016 Global Market Review Covering 227 Companies

2016-08-10 prnewswire
RnRMarketResearch.com adds "Colorectal Cancer - Pipeline Review, H1 2016" market research report to its store providing an overview and comprehensive information on the therapeutic development for Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

 
Age Related Macular Degeneration Pipeline Landscape and Therapeutics Market 2016 Review

2016-07-08 prnewswire
RnRMarketResearch.com adds "Age Related Macular Degeneration - Pipeline Review, H1 2016" offering information on comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Age Related Macular Degeneration and special features on late-stage and discontinued projects.

 
Stellar Biotechnologies: Vaccine Tech Buoyed By Partnerships

2016-06-23 seekingalpha
Stellar has undisclosed partners working in Alzheimer's disease, as well as other undisclosed oncology and autoimmune indications.

 
Pipeline of Psoriasis Market Covering 140 Companies Reviewed for H1 2016

2016-05-13 prnewswire
RnRMarketResearch.com adds "Psoriasis - Pipeline Review, H1 2016" market research report that provides an overview of the Psoriasis's therapeutic pipeline with comprehensive information and comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

 
Pipeline of Systemic Lupus Erythematosus Market Reviewed for H2 2015 in New Research Report

2016-02-18 prnewswire
PUNE, India, February 18, 2016 /PRNewswire/ -- New market research titled

 
Stellar Biotechnologies and Neovacs Propose to Form Joint Venture to Manufacture Conjugated Therapeutic Vaccines With Stellar KLH(TM)

2016-01-20 marketwired
PORT HUENEME, CA and PARIS, FRANCE and BOSTON, MA--(Marketwired - Jan 20, 2016) - Stellar Biotechnologies, Inc. ("Stellar") (NASDAQ: SBOT) (TSX VENTURE: KLH) and Neovacs S.A. ("Neovacs") (ALTERNEXT PARIS: ALNEV) today announced they have entered into a term sheet to form a joint venture for the manufacture of conjugated therapeutic...

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...